Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass
The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.
The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.
Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.
Most enrolled patients (1,583 out of 1,693; 93.5%) answered ≥1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).
Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.
KeywordsInjection Osteoporosis Preference Questionnaire Satisfaction Tablet
- 2.Wahl C, Gregoire JP, Teo K et al (2005) Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Qual 8:65–70Google Scholar
- 22.Cummings SR, McClung MR, Christiansen C et al (2008) The effects of denosumab on fracture risk in women with osteoporosis. Osteoporos Int 20:167Google Scholar
- 29.Gold DT, Horne R, Hill C et al (2008) Development, reliability, and validity of a new preference satisfaction questionnaire. J Bone Miner Res 23:S210–S211Google Scholar
- 30.Kendler DL, Benhamou CL, Brown JP et al (2008) Effects of denosumab in postmenopausal women transitioning from alendronate therapy in comparison with continued alendronate. Osteoporos Int 9(Suppl 2):S385–S386Google Scholar
- 31.Brown JP, Prince RL, Deal C et al (2008) Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res . doi:10.1359/jbmr.080910 PubMedGoogle Scholar